Shares of Annovis Bio, Inc. (NYSE:ANVS – Get Free Report) have earned a consensus recommendation of “Buy” from the six analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $31.40.
Several research analysts have recently commented on the company. Maxim Group upgraded Annovis Bio from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research report on Friday, October 25th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Annovis Bio in a report on Monday, November 11th.
Get Our Latest Research Report on Annovis Bio
Institutional Investors Weigh In On Annovis Bio
Annovis Bio Price Performance
ANVS opened at $2.94 on Wednesday. The stock has a market capitalization of $41.87 million, a PE ratio of -0.66 and a beta of 1.63. Annovis Bio has a 12-month low of $2.88 and a 12-month high of $20.00. The firm’s fifty day moving average price is $4.98 and its 200 day moving average price is $7.18.
Annovis Bio (NYSE:ANVS – Get Free Report) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.33). On average, equities research analysts forecast that Annovis Bio will post -2.19 earnings per share for the current fiscal year.
Annovis Bio Company Profile
Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.
Recommended Stories
- Five stocks we like better than Annovis Bio
- Pros And Cons Of Monthly Dividend Stocks
- 3 Volatility ETFs to Help You Profit from Market Chaos
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Lam Research: Is a NAND Upgrade Cycle the Next Growth Catalyst?
- How to Profit From Growth Investing
- Chipotle’s Slip: A Short-Term Dip or Long-Term Opportunity?
Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.